Connect with us

News

Pfizer-BioNTech COVID-19 Vaccine Remains Highly Effective After 6 Months, Trial Data Show

Published

on

WASHINGTON, April 2 – The ongoing phase three  clinical trial of Pfizer-BioNTech’s COVID-19 vaccine showed its protection remains high for up to six months after the second dose, the two companies announced on Thursday.

Results from the analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal phase three  study showed the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3 per cent effective against COVID-19, measured seven days through up to six months after the second dose, reported Xinhua news agency.

The vaccine was 100 per cent effective against severe disease as defined by the United States (US)  Centres for Disease Control and Prevention, and 95.3 per cent effective against severe COVID-19 as defined by the US Food and Drug Administration (FDA), according to a joint statement of the two companies.

Safety data from the phase three  study have been collected from more than 12,000 vaccinated participants who have a follow-up time of at least six months after the second dose, demonstrating a favourable safety and tolerability profile, said the statement.

“These data confirm the favourable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the US  FDA,” said Albert Bourla, chairman and chief executive officer of Pfizer.

“These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population,” said Ugur Sahin, CEO and co-founder of BioNTech.

The new results came a day after the two companies announced the vaccine has demonstrated 100 per cent efficacy and robust antibody responses in a trial in adolescents 12 to 15 years of age.

The trial enrolled 2,260 adolescents 12 to 15 years of age in the United States. In the trial, 18 cases of COVID-19 were observed in the placebo group versus none in the vaccinated group.

The vaccine elicited SARS-CoV-2-neutralising antibody geometric mean titers (GMTs) of 1,239.5, demonstrating strong immunogenicity in a subset of adolescents one month after the second dose, according to the companies.

The results exceeded those recorded earlier in vaccinated participants aged 16 to 25 years old, according to the trial data.

The two companies plan to submit these data to the FDA and the European Medicines Agency as soon as possible to request expansion of the Emergency Use Authorization and EU Conditional Marketing Authorization for BNT162b2.

The FDA authorised Pfizer-BioNTech COVID-19 vaccine for emergency use in the United States in December last year. The vaccine, the first that got FDA approval in the country, was authorised for use in individuals 16 years of age and older.

Source: BERNAMA

Health

More Than 20 Million of Adult Population Fully Vaccinated

Published

on

KUALA LUMPUR,  Sept 30  –A total of 20,053,472 individuals or 85.7 per cent of the adult population in the country have completed their COVID-19 vaccination as of yesterday.

Based on the Health Ministry’s data on COVIDNOW, 22,017,043 individuals or 94.1 per cent  of the adults in the country have received at least one dose of the vaccine until yesterday.

It also showed 40,206 individuals or 1.3 per cent of the adolescents, comprising those age between 12 and 17, having completed the vaccination as of yesterday.

A total of 310,661 doses of the vaccine were dispensed yesterday, with 190,599 doses as first dose and 148,062 doses to second dose recipients, bringing the number of doses dispensed under the National COVID-19 Immunisation Programme (PICK) to 43,367,580.

PICK was launched on Feb 24 this year to curb the spread of the COVID-19 pandemic.

Meanwhile, a total of 208 deaths due to COVID-19 were reported yesterday (Sept 29),  with 68 of them brought in dead (BID),  bringing the total death due to the virus in the country to 26,143.

On the total death reported yesterday, only 88  cases were the actual deaths reported for the day, while the rest were backlog cases.

Sources: BERNAMA

Continue Reading

Lifestyle

(Video) Witness Dinosaurs Back From Extinction In Sabah, This Is ‘Jurassic Land Kiulu’

Published

on

Jurrasic Land Kiulu is absolutely a brand new tourism attraction located specifically in Sabah and it is definitely Southeast Asia’s answer to the famous Jurassic Park. This is because the particular family park is actually inspired by the Jurassic Park movie franchise and it is to offer such a unique experience to all the visitors that wanted to come.

The park will feature amazing animatronic dinosaurs placed strategically around the three-acre land to aim for Jurassic Land Kiulu to become the next eco-tourism destination in Sabah. It is managed by Visiont Ventura and the particular park also would boast a cafe, flying zip-line, jumpoline, and also cycle-8 park just for public viewing.

@fanuelabelUntuk kamu yang belum tau, kalau kamu mau cari dinosor carilah di sabah, sini ada🦖 #fyp #jurassiclandkiulu #sabahancrew_fams♬ Welcome to Jurassic World – Michael Giacchino

This dino-themed family attraction will be the talk of Kota Kinabalu as it lies in the Tuaran district. In a matter of fact, Kiulu was finally selected due to the natural environment and also eco-tourism opportunities there. To make things more interesting from the park, all the visitors would have unobstructed views of majestic Mount Kinabalu.

Dinosaurs that are found there:

  1. Tyrannosaurus Rex
  2. Velociraptor
  3. Pteranodon
  4. Triceratops
  5. Stegosaurus
  6. Spinosaurus
  7. Dilophosaurus
  8. Ankylosaurus

Jurassic Park Kiulu Address:

Kg Bungalio
KM 3.5 Jalan Kiulu Tamparuli
89250 Sabah, Malaysia

1. Weekday Ticket Prices (Adult – RM25, Children & Seniors – RM15)

2. Weekend, Public and School Holidays (Adult – RM35, Children & Seniors – RM25)

3. Annual Pass (Adult – RM150, Children & Seniors – RM100)

Sources: TikTok Fanuel Abel, Facebook Jurassic Land Kiulu.

Continue Reading

News

Malaysian Ambassador To Lebanon Hands Over Letter of Appointment To President

Published

on

KUALA LUMPUR, Sept 29 —  The new Malaysian Ambassador to Lebanon, Azri Mat Yacob, handed over the letter of appointment to the President of the Republic of Lebanon Michel Aoun in a ceremony, yesterday.

During a meeting with the President after handing over the letter, Azri underlined that he will continue to work to further strengthen existing bilateral relations, as well as strengthen cooperation at the international level and trade relations between the two countries.

According to a statement from the Malaysian Embassy in Lebanon sent to Bernama through Wisma Putra, Aoun welcomed the commitment and also expressed his hope that cooperation between the two countries could be further enhanced in the future.

“Diplomatic relations between the two countries were established in 1965 and since then, the two countries have established good and friendly relations.” said the statement.

The Malaysian Embassy in Beirut was opened in 2005 and a total of 850 officers and members of the Malaysian Battalion (MALBATT) were also in Southern Lebanon to maintain peace and carry out the United Nations Interim Force in Lebanon (UNIFIL) mission.

Since 2007, the MALBATT team has been involved as one of the peacekeepers to enforce United Nations Security Council Resolution 1701.

Azri started his career as an Administrative and Diplomatic Officer and served in the Ministry of Foreign Affairs since 2001. Prior to his appointment as Malaysian Ambassador to Lebanon, he was the Secretary of the Communications and Public Diplomacy Division, Wisma Putra.

Sources: BERNAMA

Continue Reading

Trending